t(6;14)(q15;q32) in a patient with CD5+CD10+ diffuse large B-cell lymphoma

Miyuki Hayama1, Nozomi Niitsu, Masaaki Higashihara

  • 1Department of Hematology, Kitasato University, Sagamihara-shi, Kanagawa, Japan. mhayama@med.kitasato-u.ac.jp

Insights

This study reports a rare case of CD5-positive, CD10-positive diffuse large B-cell lymphoma in a patient with hereditary spherocytosis. The lymphoma exhibited a unique chromosomal translocation, t(6;14)(q15;q32), highlighting the need for further research into lymphomagenesis mechanisms.

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
  • Co-occurrence of DLBCL with hereditary spherocytosis is uncommon.
  • Specific immunophenotypic and cytogenetic profiles can influence DLBCL behavior and prognosis.

Observation:

  • A 68-year-old male presented with systemic lymphadenopathy.
  • Cervical lymph node biopsy revealed diffuse proliferation of large atypical lymphoid cells.
  • Immunohistochemistry showed positivity for CD5, CD10, CD20, CD79a, and Bcl2, and negativity for CD3 and cyclin D1.

Findings:

  • The patient was diagnosed with CD5+, CD10+ diffuse large B-cell lymphoma.
  • Karyotypic analysis revealed complex chromosomal abnormalities, including add(5)(q13), del(6)(q13), add(17)(p11), add(19)(p11), add(19)(p13), and a non-random t(6;14)(q15;q32) translocation.
  • Peripheral blood smear showed elliptocytosis, and a family history confirmed hereditary spherocytosis.

Implications:

  • The presence of CD5 and CD10 markers in DLBCL, along with the specific t(6;14)(q15;q32) translocation, suggests a distinct subtype requiring further investigation.
  • Understanding the lymphomagenesis mechanism in such cases is crucial for developing targeted therapies.
  • The co-occurrence with hereditary spherocytosis warrants exploration of potential shared pathways or independent disease processes.